Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone801-994-7383
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$430,000.00
Profitability
Miscellaneous
Employees10
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Lipocine (NASDAQ:LPCN) Frequently Asked Questions
What is Lipocine's stock symbol?
Lipocine trades on the NASDAQ under the ticker symbol "LPCN."
How were Lipocine's earnings last quarter?
Lipocine Inc (NASDAQ:LPCN) posted its quarterly earnings data on Wednesday, August, 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.07. View Lipocine's Earnings History.
When is Lipocine's next earnings date?
What price target have analysts set for LPCN?
2 brokers have issued 1 year price objectives for Lipocine's stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Lipocine's share price to reach $5.00 in the next year. This suggests a possible upside of 74.2% from the stock's current price. View Analyst Price Targets for Lipocine.
What is the consensus analysts' recommendation for Lipocine?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Lipocine.
Has Lipocine been receiving favorable news coverage?
News stories about LPCN stock have been trending somewhat negative on Monday, InfoTrie Sentiment reports. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Lipocine earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Lipocine.
Who are some of Lipocine's key competitors?
Some companies that are related to Lipocine include Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), Xeris Pharmaceuticals (XERS), CV Sciences (CVSI), ProQR Therapeutics (PRQR), TapImmune (MRKR), Geron (GERN), Seres Therapeutics (MCRB), Clovis Oncology (CLVS), Recro Pharma (REPH), Evofem Biosciences (EVFM), Evelo Biosciences (EVLO), Concert Pharmaceuticals (CNCE), Kalvista Pharmaceuticals (KALV) and MannKind (MNKD).
What other stocks do shareholders of Lipocine own?
Who are Lipocine's key executives?
Lipocine's management team includes the folowing people:
- Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)
- Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)
- Logan Morse, VP of Sales, Marketing & Operations (Age 49)
- Nachiappan Chidambaram, VP of Product Devel. (Age 50)
- Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88)
Who are Lipocine's major shareholders?
Lipocine's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.24%), Renaissance Technologies LLC (2.00%), BlackRock Inc. (1.47%), Susquehanna International Group LLP (0.09%) and FNY Investment Advisers LLC (0.06%). Company insiders that own Lipocine stock include Gregory Brooks Bass, Jeffrey Arvin Fink, Mahesh V Patel, Morgan R Brown and Stephen A Hill. View Institutional Ownership Trends for Lipocine.
Which major investors are selling Lipocine stock?
Which major investors are buying Lipocine stock?
LPCN stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Vanguard Group Inc., BlackRock Inc. and FNY Investment Advisers LLC. View Insider Buying and Selling for Lipocine.
How do I buy shares of Lipocine?
Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Lipocine's stock price today?
One share of LPCN stock can currently be purchased for approximately $2.87.
How big of a company is Lipocine?
Lipocine has a market capitalization of $71.29 million and generates $430,000.00 in revenue each year. The specialty pharmaceutical company earns $-11,660,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Lipocine employs 10 workers across the globe.View Additional Information About Lipocine.
What is Lipocine's official website?
How can I contact Lipocine?
Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]
MarketBeat Community Rating for Lipocine (NASDAQ LPCN)
MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote "Outperform" if you believe LPCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
